45 related articles for article (PubMed ID: 16082189)
1. Signal therapy of breast cancers by the HDAC inhibitor FK228 that blocks the activation of PAK1 and abrogates the tamoxifen-resistance.
Hirokawa Y; Arnold M; Nakajima H; Zalcberg J; Maruta H
Cancer Biol Ther; 2005 Sep; 4(9):956-60. PubMed ID: 16082189
[TBL] [Abstract][Full Text] [Related]
2. Rapamycin vs TORin-1 or Gleevec vs Nilotinib: Simple chemical evolution that converts PAK1-blockers to TOR-blockers or vice versa?
Maruta H; He H
Drug Discov Ther; 2024 Jun; 18(2):134-139. PubMed ID: 38569833
[TBL] [Abstract][Full Text] [Related]
3. SERPINA3-ANKRD11-HDAC3 pathway induced aromatase inhibitor resistance in breast cancer can be reversed by HDAC3 inhibition.
Zhou J; Zhu M; Wang Q; Deng Y; Liu N; Liu Y; Liu Q
Commun Biol; 2023 Jul; 6(1):695. PubMed ID: 37414914
[TBL] [Abstract][Full Text] [Related]
4. The paradigm of drug resistance in cancer: an epigenetic perspective.
Adhikari S; Bhattacharya A; Adhikary S; Singh V; Gadad SS; Roy S; Das C
Biosci Rep; 2022 Apr; 42(4):. PubMed ID: 35438143
[TBL] [Abstract][Full Text] [Related]
5. Herbal immune-boosters: Substantial warriors of pandemic Covid-19 battle.
Khanna K; Kohli SK; Kaur R; Bhardwaj A; Bhardwaj V; Ohri P; Sharma A; Ahmad A; Bhardwaj R; Ahmad P
Phytomedicine; 2021 May; 85():153361. PubMed ID: 33485605
[TBL] [Abstract][Full Text] [Related]
6. Chemical carcinogen-induced rat mammary carcinogenesis is a potential model of p21-activated kinase positive female breast cancer.
Duderstadt EL; McQuaide SA; Sanders MA; Samuelson DJ
Physiol Genomics; 2021 Feb; 53(2):61-68. PubMed ID: 33346690
[TBL] [Abstract][Full Text] [Related]
7. Endocrine Resistance in Breast Cancer: The Role of Estrogen Receptor Stability.
Jeffreys SA; Powter B; Balakrishnar B; Mok K; Soon P; Franken A; Neubauer H; de Souza P; Becker TM
Cells; 2020 Sep; 9(9):. PubMed ID: 32932819
[TBL] [Abstract][Full Text] [Related]
8. PAK1-blockers: Potential Therapeutics against COVID-19.
Maruta H; He H
Med Drug Discov; 2020 Jun; 6():100039. PubMed ID: 32313880
[TBL] [Abstract][Full Text] [Related]
9. Combined inhibition of Aurora A and p21-activated kinase 1 as a new treatment strategy in breast cancer.
Korobeynikov V; Borakove M; Feng Y; Wuest WM; Koval AB; Nikonova AS; Serebriiskii I; Chernoff J; Borges VF; Golemis EA; Shagisultanova E
Breast Cancer Res Treat; 2019 Sep; 177(2):369-382. PubMed ID: 31254157
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic potential of Pak1 inhibition for pain associated with cutaneous burn injury.
Guo Y; Benson C; Hill M; Henry S; Effraim P; Waxman SG; Dib-Hajj S; Tan AM
Mol Pain; 2018; 14():1744806918788648. PubMed ID: 29956587
[TBL] [Abstract][Full Text] [Related]
11. Crosstalk among the proteome, lysine phosphorylation, and acetylation in romidepsin-treated colon cancer cells.
Wang TY; Chai YR; Jia YL; Gao JH; Peng XJ; Han HF
Oncotarget; 2016 Aug; 7(33):53471-53501. PubMed ID: 27472459
[TBL] [Abstract][Full Text] [Related]
12. Use of class I histone deacetylase inhibitor romidepsin in combination regimens.
Petrich A; Nabhan C
Leuk Lymphoma; 2016 Aug; 57(8):1755-65. PubMed ID: 27118119
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of aromatase inhibitor resistance.
Ma CX; Reinert T; Chmielewska I; Ellis MJ
Nat Rev Cancer; 2015 May; 15(5):261-75. PubMed ID: 25907219
[TBL] [Abstract][Full Text] [Related]
14. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
Raha P; Thomas S; Thurn KT; Park J; Munster PN
Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
[TBL] [Abstract][Full Text] [Related]
15. PAK signalling during the development and progression of cancer.
Radu M; Semenova G; Kosoff R; Chernoff J
Nat Rev Cancer; 2014 Jan; 14(1):13-25. PubMed ID: 24505617
[TBL] [Abstract][Full Text] [Related]
16. Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer.
Johansson HJ; Sanchez BC; Mundt F; Forshed J; Kovacs A; Panizza E; Hultin-Rosenberg L; Lundgren B; Martens U; Máthé G; Yakhini Z; Helou K; Krawiec K; Kanter L; Hjerpe A; Stål O; Linderholm BK; Lehtiö J
Nat Commun; 2013; 4():2175. PubMed ID: 23868472
[TBL] [Abstract][Full Text] [Related]
17. Untangling the complexity of PAK1 dynamics: The future challenge.
Parrini MC
Cell Logist; 2012 Apr; 2(2):78-83. PubMed ID: 23125950
[TBL] [Abstract][Full Text] [Related]
18. Molecular pathways: targeting p21-activated kinase 1 signaling in cancer--opportunities, challenges, and limitations.
Eswaran J; Li DQ; Shah A; Kumar R
Clin Cancer Res; 2012 Jul; 18(14):3743-9. PubMed ID: 22595609
[TBL] [Abstract][Full Text] [Related]
19. The enhanced antiproliferative response to combined treatment of trichostatin A with raloxifene in MCF-7 breast cancer cells and its relevance to estrogen receptor β expression.
Tu Z; Li H; Ma Y; Tang B; Tian J; Akers W; Achilefu S; Gu Y
Mol Cell Biochem; 2012 Jul; 366(1-2):111-22. PubMed ID: 22476901
[TBL] [Abstract][Full Text] [Related]
20. A new synthetic HDAC inhibitor, MHY218, induces apoptosis or autophagy-related cell death in tamoxifen-resistant MCF-7 breast cancer cells.
Park JH; Ahn MY; Kim TH; Yoon S; Kang KW; Lee J; Moon HR; Jung JH; Chung HY; Kim HS
Invest New Drugs; 2012 Oct; 30(5):1887-98. PubMed ID: 21983700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
